Heterodimers of G protein-coupled receptors as novel and distinct drug targets

Drug Discovery Today: Therapeutic Strategies

Volumn 3, Issue 4, 2006, Pages 437-443

  Rozenfeld, Raphael ^a   Décaillot, Fabien M ^a   IJzerman, Adriaan P ^b   Devi, Lakshmi A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

5' GUANIDINONALTRINDOLE; 6' GUANIDINONALTRINDOLE; 8 [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] 8 AZASPIRO[4.5]DECANE 7,9 DIONE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ALLOSTERIC MODULATOR; CGP 7930; CYCLAMATE SODIUM; DELTA OPIATE RECEPTOR ANTAGONIST; G PROTEIN COUPLED RECEPTOR; GS 39783; HETERODIMER; HOMODIMER; INDOLE DERIVATIVE; ISOPRENALINE; KDN 21; LIGAND; MORPHINE; NALTRINDOLE; OXYMORPHONE; SUCROSE; UNCLASSIFIED DRUG; VALSARTAN;

DIMERIZATION; DRUG DESIGN; DRUG SELECTIVITY; DRUG TARGETING; IN VIVO STUDY; PROTEIN EXPRESSION; RECEPTOR BINDING; REVIEW;

EID: 33846148639     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2006.11.001     Document Type: Review

References (41)

1. Drews J. Genomic sciences and the medicine of tomorrow. Nat. Biotechnol. 14 (1996) 1516-1518
2. Pierce K.L., et al. Seven-transmembrane receptors. Nat. Rev. Mol. Cell Biol. 3 (2002) 639-650
3. Hill S.J. G-protein-coupled receptors: past, present and future. Br. J. Pharmacol. 147 Suppl 1 (2006) S27-S37
4. Devi L.A. Heterodimerization of G-protein-coupled receptors: pharmacology, signaling and trafficking. Trends Pharmacol. Sci. 22 (2001) 532-537
5. Milligan G. G protein-coupled receptor dimerization: function and ligand pharmacology. Mol. Pharmacol. 66 (2004) 1-7
6. Prinster S.C., et al. Heterodimerization of G protein-coupled receptors: specificity and functional significance. Pharmacol. Rev. 57 (2005) 289-298
7. Bulenger S., et al. Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. Trends Pharmacol. Sci. 26 (2005) 131-137
8. Jones K.A., et al. GABAB receptors function as a heteromeric assembly of the subunits GABABR1 and GABABR2. Nature 396 (1998) 674-679
9. Kaupmann K., et al. GABAB-receptor subtypes assemble into functional heteromeric complexes. Nature 396 (1998) 683-687
10. White J.H., et al. Heterodimerization is required for the formation of a functional GABAB receptor. Nature 396 (1998) 679-682
11. Kuner R., et al. Role of heteromer formation in GABAB receptor function. Science 283 (1999) 74-77
12. Nelson G., et al. An amino-acid taste receptor. Nature 416 (2002) 199-202
13. Nelson G., et al. Mammalian sweet taste receptors. Cell 106 (2001) 381-390
14. Uberti M.A., et al. Heterodimerization with beta2-adrenergic receptors promotes surface expression and functional activity of alpha1D-adrenergic receptors. J. Pharmacol. Exp. Ther. 313 (2005) 16-23
15. Christopoulos A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat. Rev. Drug Discov. 1 (2002) 198-210
16. Soudijn W., et al. Allosteric modulation of G protein-coupled receptors: perspectives and recent developments. Drug Discov. Today 9 (2004) 752-758
17. Jordan B.A., and Devi L.A. G-protein-coupled receptor heterodimerization modulates receptor function. Nature 399 (1999) 697-700
18. George S.R., et al. Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties. J. Biol. Chem. 275 (2000) 26128-26135
19. Gomes I., et al. Heterodimerization of mu and delta opioid receptors: A role in opiate synergy. J. Neurosci. 20 (2000) RC110
20. Gomes I., et al. A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proc. Natl. Acad. Sci. U S A 101 (2004) 5135-5139
21. Pfeiffer M., et al. Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst3 receptor function by heterodimerization with sst(2A). J. Biol. Chem. 276 (2001) 14027-14036
22. McGraw D.W., et al. Airway smooth muscle prostaglandin-EP1 receptors directly modulate beta2-adrenergic receptors within a unique heterodimeric complex. J. Clin. Invest. 116 (2006) 1400-1409
23. AbdAlla S., et al. AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature 407 (2000) 94-98
24. Rocheville M., et al. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288 (2000) 154-157
25. Jordan B.A., et al. Functional interactions between mu opioid and alpha 2A-adrenergic receptors. Mol. Pharmacol. 64 (2003) 1317-1324
26. AbdAlla S., et al. Increased AT1 receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat. Med. 7 (2001) 1003-1009
27. Bernstein K.E. Views of the renin-angiotensin system: brilling, mimsy, and slithy tove. Hypertension 47 (2006) 509-514
28. Barki-Harrington L., et al. Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo. Circulation 108 (2003) 1611-1618
29. Zhu W.Z., et al. Heterodimerization of beta1- and beta2-adrenergic receptor subtypes optimizes beta-adrenergic modulation of cardiac contractility. Circ. Res. 97 (2005) 244-251
30. Abdelhamid E.E., and Takemori A.E. Characteristics of mu and delta opioid binding sites in striatal slices of morphine-tolerant and -dependent mice. Eur. J. Pharmacol. 198 (1991) 157-163
31. Daniels D.J., et al. Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc. Natl. Acad. Sci. U S A 102 (2005) 19208-19213
32. Miaskowski C., et al. Kappa- and delta-opioid agonists synergize to produce potent analgesia. Brain Res. 509 (1990) 165-168
33. Wessendorf M.W., and Dooyema J. Coexistence of kappa- and delta-opioid receptors in rat spinal cord axons. Neurosci. Lett. 298 (2001) 151-154
34. Bhushan R.G., et al. A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers. J. Med. Chem. 47 (2004) 2969-2972
35. Xie Z., et al. Interaction of bivalent ligand KDN21 with heterodimeric delta-kappa opioid receptors in human embryonic kidney 293 cells. Mol. Pharmacol. 68 (2005) 1079-1086
36. Lipinski C.A., et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46 (2001) 3-26
37. Waldhoer M., et al. A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc. Natl. Acad. Sci. U S A 102 (2005) 9050-9055
38. B receptors in anxiety and depression. Trends Pharmacol. Sci. 26 (2005) 36-43
39. Hague C., et al. Heterodimers of alpha1B- and alpha1D-adrenergic receptors form a single functional entity. Mol. Pharmacol. 69 (2006) 45-55
40. Novi F., et al. Paired activation of two components within muscarinic M3 receptor dimers is required for recruitment of beta-arrestin-1 to the plasma membrane. J. Biol. Chem. 280 (2005) 19768-19776
41. Small K.M., et al. Alpha2A- and alpha2C-adrenergic receptors form homo- and heterodimers: the heterodimeric state impairs agonist-promoted GRK phosphorylation and beta-arrestin recruitment. Biochemistry 45 (2006) 4760-4767